MedPath

Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Phase 4
Terminated
Conditions
Myocardial Infarct
Hyperglycemia
Registration Number
NCT00237471
Lead Sponsor
Melbourne Health
Brief Summary

To determine whether tight glycaemic control with insulin improves myocardial function and myocardial perfusion (measured by myocardial contrast echocardiography) and novel vascular risk factors in patients with acute myocardial infarction and hyperglycaemia.

Detailed Description

We will randomise patients with acute myocardial infarction and blood glucose levels (BGLs) \>=10mmol/L within 24 hours of pain onset, to either tight glucose control (aiming BGLs 4.5 - 7mmol/L) with an insulin infusion (for 24 hours) followed by subcutaneous insulin or standard control (BGL 6 - 12mmol/L) without the use of an insulin infusion. Serial myocardial contrast echocardiography will measure changes in myocardial perfusion and function from baseline to 3 months between each group. We will also measure changes in inflammatory and endothelial markers over this time to see whether tight glucose control improves these surrogate endpoints.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Age >=18years
  • Acute Myocardial Infarction
  • Blood Glucose Level >=10mmol/L
  • Wall motion abnormality on baseline echocardiogram
Exclusion Criteria
  • Active infection/inflammation
  • Cardiac shunt
  • Cognitive Impairment
  • Insulin allergy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Difference in the change in wall motion score index between admission, day 3-5 and after 3 months in the two treatment arms.
Secondary Outcome Measures
NameTimeMethod
Changes in inflammatory/endothelial markers and myocardial perfusion from admission, day 3-5 and after 3 months between the two treatment arms

Trial Locations

Locations (1)

The Royal Melbourne Hospital

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath